Standard BioToolsLAB +5.30%35 EV-to-FCF is 0.72 as of Jul. 02, 2026. GuruFocus rates LAB with a GF Score™ of 35/100 and a GF Value™ of $0.53 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Standard BioTools ranks better than 97.36% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Standard BioTools's Enterprise Value is $-68.32 Mil.
Standard BioTools's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-94.48 Mil. Therefore, Standard BioTools's EV-to-FCF for today is 0.72.
The historical rank and industry rank for Standard BioTools's EV-to-FCF or its related term are showing as below:
LAB'
s EV-to-FCF Range Over the Past 10 Years
Min: -32.33 Med: -6.31 Max: 1.49
Current: 0.72
During the past 13 years, the highest EV-to-FCF of Standard BioTools was 1.49. The lowest was -32.33. And the median was -6.31.
LAB's EV-to-FCF is ranked better than 97.36% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 22.52
vs LAB: 0.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Standard BioTools's PE Ratio (TTM) for today is calculated as:
Standard BioTools's share price for today is $0.9129.
Standard BioTools's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Standard BioTools EV-to-FCF Related Terms
Standard BioTools EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Standard BioTools's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Standard BioTools's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Standard BioTools's EV-to-FCF falls into.
Standard BioTools's current Enterprise Value is $-68.32 Mil.
Standard BioTools's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-94.48 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (LAB) has a EV-to-FCF of 0.72 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #11 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 2.6%.
Is Standard BioTools' EV-to-FCF too high?
Standard BioTools' current EV-to-FCF is 0.72. The Medical Devices & Instruments industry median EV-to-FCF is 22.52. Standard BioTools' value of 0.72 is 96.8% below this industry median. Based on the distribution chart, Standard BioTools ranks #11 out of 417 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Standard BioTools has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' EV-to-FCF compare to SENS and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #11 out of 417 companies for EV-to-FCF. This places Standard BioTools in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 22.52. Standard BioTools' value of 0.72 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Standard BioTools's current EV-to-FCF of 0.72 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current EV-to-FCF is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.53, compared to a current price of $0.91 — trading 72.2% above its estimated fair value. The current EV-to-FCF is 0.72 and 96.8% below the Medical Devices & Instruments industry median of 22.52. Standard BioTools' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Standard BioTools (LAB), the current EV-to-FCF is 0.72 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of $0.91 is trading 72.2% above its estimated GF Value™ of $0.53.
GuruFocus considers Standard BioTools to be Significantly Overvalued.
Key valuation signals for LAB:
EV-to-FCF: 0.72
GF Value™: $0.53 vs. price of $0.91 (72.2% above fair value)
Industry Position: 96.8% below the Medical Devices & Instruments median (#11 of 417)
No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
35GF Score
Get the complete analysis for LAB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LAB has been successfully added to your 
